Učitavanje...
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
BACKGROUND: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. METHODS: Participants (n = 216) with baseline hemoglobi...
Spremljeno u:
| Izdano u: | Clin Kidney J |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366140/ https://ncbi.nlm.nih.gov/pubmed/30746141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy014 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|